PH27150A - Osmotic continuous dispensing oral delivery system containing a pharmaceutically acceptable active agent having improved core membrane adhesion properties - Google Patents
Osmotic continuous dispensing oral delivery system containing a pharmaceutically acceptable active agent having improved core membrane adhesion properties Download PDFInfo
- Publication number
- PH27150A PH27150A PH38540A PH38540A PH27150A PH 27150 A PH27150 A PH 27150A PH 38540 A PH38540 A PH 38540A PH 38540 A PH38540 A PH 38540A PH 27150 A PH27150 A PH 27150A
- Authority
- PH
- Philippines
- Prior art keywords
- metoprolol
- core
- cellulose
- tablet
- salt
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title claims description 10
- 230000003204 osmotic effect Effects 0.000 title abstract description 7
- 239000012528 membrane Substances 0.000 title description 21
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims abstract description 36
- 229960002237 metoprolol Drugs 0.000 claims abstract description 26
- 239000011248 coating agent Substances 0.000 claims abstract description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 28
- 229920002678 cellulose Polymers 0.000 claims description 19
- 239000001913 cellulose Substances 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000000576 coating method Methods 0.000 claims description 8
- BRIPGNJWPCKDQZ-WXXKFALUSA-N (e)-but-2-enedioic acid;1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol Chemical group OC(=O)\C=C\C(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 BRIPGNJWPCKDQZ-WXXKFALUSA-N 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 229960002005 metoprolol fumarate Drugs 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 3
- 241001508691 Martes zibellina Species 0.000 claims description 2
- -1 hydroxypropylmethyl Chemical group 0.000 claims description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 241001233887 Ania Species 0.000 claims 1
- 101100298995 Arabidopsis thaliana PBC1 gene Proteins 0.000 claims 1
- 241000209761 Avena Species 0.000 claims 1
- 235000007319 Avena orientalis Nutrition 0.000 claims 1
- 101100205847 Mus musculus Srst gene Proteins 0.000 claims 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims 1
- 235000017276 Salvia Nutrition 0.000 claims 1
- 241001072909 Salvia Species 0.000 claims 1
- 241000607479 Yersinia pestis Species 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- BBXRRTJNJCPGBU-UHFFFAOYSA-N beta-naphthyl N-acetylphenylalaninate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=O)C(NC(=O)C)CC1=CC=CC=C1 BBXRRTJNJCPGBU-UHFFFAOYSA-N 0.000 claims 1
- 101150010415 eat-5 gene Proteins 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 235000003642 hunger Nutrition 0.000 claims 1
- 235000020129 lassi Nutrition 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000011148 porous material Substances 0.000 claims 1
- 210000004916 vomit Anatomy 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract description 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract description 2
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 241000206607 Porphyra umbilicalis Species 0.000 description 17
- 239000011230 binding agent Substances 0.000 description 15
- 235000010980 cellulose Nutrition 0.000 description 14
- 229940081735 acetylcellulose Drugs 0.000 description 12
- 229920002301 cellulose acetate Polymers 0.000 description 11
- 239000000463 material Substances 0.000 description 8
- 229940022663 acetate Drugs 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 6
- 241000518994 Conta Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- WUBVEMGCQRSBBT-UHFFFAOYSA-N tert-butyl 4-(trifluoromethylsulfonyloxy)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(OS(=O)(=O)C(F)(F)F)=CC1 WUBVEMGCQRSBBT-UHFFFAOYSA-N 0.000 description 3
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229960001300 metoprolol tartrate Drugs 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- ZAMLGGRVTAXBHI-UHFFFAOYSA-N 3-(4-bromophenyl)-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(CC(O)=O)C1=CC=C(Br)C=C1 ZAMLGGRVTAXBHI-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920002284 Cellulose triacetate Polymers 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 101100346656 Drosophila melanogaster strat gene Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- 241000183024 Populus tremula Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 240000003864 Ulex europaeus Species 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
- CBICCXFXCXELAR-UHFFFAOYSA-N acetic acid;ethyl hydrogen carbonate Chemical compound CC(O)=O.CCOC(O)=O CBICCXFXCXELAR-UHFFFAOYSA-N 0.000 description 1
- ZXPJBQLFCRVBDR-UHFFFAOYSA-N acetic acid;methanesulfonic acid Chemical compound CC(O)=O.CS(O)(=O)=O ZXPJBQLFCRVBDR-UHFFFAOYSA-N 0.000 description 1
- MFOPEVCFSVUADB-UHFFFAOYSA-N acetic acid;methyl carbamate Chemical compound CC(O)=O.COC(N)=O MFOPEVCFSVUADB-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000002361 compost Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000032798 delamination Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Confectionery (AREA)
- External Artificial Organs (AREA)
- Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/185,564 US4892739A (en) | 1988-04-25 | 1988-04-25 | Osmotic continuous dispensing oral delivery system containing a pharmaceutically acceptable active agent having a improved core membrane adhesion properties |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH27150A true PH27150A (en) | 1993-04-02 |
Family
ID=22681522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH38540A PH27150A (en) | 1988-04-25 | 1989-04-20 | Osmotic continuous dispensing oral delivery system containing a pharmaceutically acceptable active agent having improved core membrane adhesion properties |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US4892739A (xx) |
| EP (1) | EP0339506B1 (xx) |
| JP (1) | JP2750150B2 (xx) |
| KR (1) | KR0125935B1 (xx) |
| AT (1) | ATE75939T1 (xx) |
| AU (1) | AU618083B2 (xx) |
| CA (1) | CA1334382C (xx) |
| DD (1) | DD288093A5 (xx) |
| DE (1) | DE58901373D1 (xx) |
| DK (1) | DK175232B1 (xx) |
| ES (1) | ES2031302T3 (xx) |
| FI (1) | FI90203C (xx) |
| GR (1) | GR3005399T3 (xx) |
| HU (1) | HU201469B (xx) |
| IE (1) | IE61223B1 (xx) |
| IL (1) | IL90019A (xx) |
| MX (1) | MX15754A (xx) |
| NO (1) | NO175186C (xx) |
| NZ (1) | NZ228845A (xx) |
| PH (1) | PH27150A (xx) |
| PT (1) | PT90341B (xx) |
| ZA (1) | ZA892998B (xx) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023076A (en) * | 1987-02-27 | 1991-06-11 | Alza Corporation | Lamina comprising carboxyvinyl polymer |
| US5156850A (en) * | 1990-08-31 | 1992-10-20 | Alza Corporation | Dosage form for time-varying patterns of drug delivery |
| US5232705A (en) * | 1990-08-31 | 1993-08-03 | Alza Corporation | Dosage form for time-varying patterns of drug delivery |
| US6764697B1 (en) * | 1991-06-27 | 2004-07-20 | Alza Corporation | System for delaying drug delivery up to seven hours |
| DE69425453T2 (de) * | 1993-04-23 | 2001-04-12 | Novartis Ag, Basel | Wirkstoffabgabevorrichtung mit gesteuerter Freigabe |
| US8524277B2 (en) * | 1998-03-06 | 2013-09-03 | Alza Corporation | Extended release dosage form |
| US6099859A (en) | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
| US6099862A (en) | 1998-08-31 | 2000-08-08 | Andrx Corporation | Oral dosage form for the controlled release of a biguanide and sulfonylurea |
| SE0003125D0 (sv) * | 2000-09-05 | 2000-09-05 | Astrazeneca Ab | Modified polymers |
| US6866866B1 (en) * | 2000-11-03 | 2005-03-15 | Andrx Labs, Llc | Controlled release metformin compositions |
| US6790459B1 (en) | 2000-11-03 | 2004-09-14 | Andrx Labs, Llc | Methods for treating diabetes via administration of controlled release metformin |
| WO2002036100A1 (en) | 2000-11-03 | 2002-05-10 | Andrx Corporation | Controlled release metformin compositions |
| US20060034922A1 (en) * | 2000-11-03 | 2006-02-16 | Andrx Labs, Llc | Controlled release metformin compositions |
| US6610326B2 (en) | 2001-02-16 | 2003-08-26 | Andrx Corporation | Divalproex sodium tablets |
| KR20040018394A (ko) * | 2001-07-04 | 2004-03-03 | 썬 파마슈티컬 인더스트리스 리미티드 | 위 정체 제어되는 약물 전달 계 |
| GB2384986B (en) * | 2002-02-12 | 2004-01-07 | Reckitt Benckiser Healthcare | Compositions for the treatment of disorders of the upper gastrointestinal tract |
| AU2003241537A1 (en) * | 2002-05-23 | 2003-12-12 | Andrx Corporation | Biguanide formulations |
| US20050051922A1 (en) * | 2002-09-20 | 2005-03-10 | Avinash Nangia | Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same |
| US20050048119A1 (en) * | 2002-09-20 | 2005-03-03 | Avinash Nangia | Controlled release composition with semi-permeable membrane and poloxamer flux enhancer |
| KR20120034211A (ko) | 2002-09-20 | 2012-04-10 | 안드렉스 랩스 엘엘씨 | 약제학적 정제 |
| AU2003903507A0 (en) * | 2003-07-08 | 2003-07-24 | U. S. Filter Wastewater Group, Inc. | Membrane post-treatment |
| US7314640B2 (en) * | 2003-07-11 | 2008-01-01 | Mongkol Sriwongjanya | Formulation and process for drug loaded cores |
| US20050196446A1 (en) * | 2004-03-05 | 2005-09-08 | Huang Hai Y. | Polymeric compositions and dosage forms comprising the same |
| EP1729738B1 (en) * | 2004-03-05 | 2009-07-01 | McNeil-PPC, Inc. | Polymeric compositions and dosage forms comprising the same |
| US20050196447A1 (en) * | 2004-03-05 | 2005-09-08 | Huang Hai Y. | Polymeric compositions and dosage forms comprising the same |
| US20050196448A1 (en) * | 2004-03-05 | 2005-09-08 | Hai Yong Huang | Polymeric compositions and dosage forms comprising the same |
| US20050196442A1 (en) * | 2004-03-05 | 2005-09-08 | Huang Hai Y. | Polymeric compositions and dosage forms comprising the same |
| US20050287185A1 (en) * | 2004-06-23 | 2005-12-29 | David Wong | Extended release oxybutynin formulation |
| EP1773477B1 (en) * | 2004-07-05 | 2011-09-07 | Siemens Water Technologies Corp. | Hydrophilic membranes |
| IL166114A0 (en) * | 2005-01-03 | 2006-01-15 | Calcident Active Ltd | Long-acting controlled-release pharmaceutical preparation for use in the oral cavity |
| CN102670539A (zh) * | 2011-03-14 | 2012-09-19 | 北京天衡药物研究院 | 琥珀酸美托洛尔渗透泵控释片 |
| CN102670555A (zh) * | 2011-03-14 | 2012-09-19 | 北京天衡药物研究院 | 富马酸美托洛尔渗透泵控释片 |
| CN104684632A (zh) | 2012-09-14 | 2015-06-03 | 伊沃夸水处理技术有限责任公司 | 用于膜的聚合物共混物 |
| CA2936746C (en) | 2014-10-31 | 2017-06-27 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
| EP3322511B1 (en) | 2015-07-14 | 2022-09-07 | Rohm & Haas Electronic Materials Singapore Pte. Ltd | Aeration device for filtration system |
| JP2021531297A (ja) * | 2018-07-24 | 2021-11-18 | バイエル・アクチエンゲゼルシヤフト | 経口投与可能であり、修飾された放出を有する薬学的投薬形態 |
| US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
| WO2022060909A1 (en) * | 2020-09-15 | 2022-03-24 | Synagile Corporation | Devices and methods for continuous extrusion of a drug into the mouth |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4256108A (en) * | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4326525A (en) * | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US4439195A (en) * | 1980-10-14 | 1984-03-27 | Alza Corporation | Theophylline therapy |
| US4449983A (en) * | 1982-03-22 | 1984-05-22 | Alza Corporation | Simultaneous delivery of two drugs from unit delivery device |
| US4455143A (en) * | 1982-03-22 | 1984-06-19 | Alza Corporation | Osmotic device for dispensing two different medications |
| US4578075A (en) * | 1982-12-20 | 1986-03-25 | Alza Corporation | Delivery system housing a plurality of delivery devices |
| US4681583A (en) * | 1982-12-20 | 1987-07-21 | Alza Corporation | System for dispersing drug in biological environment |
| US4576604A (en) * | 1983-03-04 | 1986-03-18 | Alza Corporation | Osmotic system with instant drug availability |
| SE457505B (sv) * | 1984-01-10 | 1989-01-09 | Lejus Medical Ab | Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning |
| EP0153105B1 (en) * | 1984-02-10 | 1992-09-09 | Benzon Pharma A/S | Diffusion coated multiple-units dosage form |
| DK62184D0 (da) * | 1984-02-10 | 1984-02-10 | Benzon As Alfred | Diffusionsovertrukket polydepotpraeparat |
| US4609374A (en) * | 1985-04-22 | 1986-09-02 | Alza Corporation | Osmotic device comprising means for governing initial time of agent release therefrom |
| US4693886A (en) * | 1985-04-22 | 1987-09-15 | Alza Corporation | Osmotic device with inert core |
| SE455836B (sv) * | 1985-10-11 | 1988-08-15 | Haessle Ab | Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning |
| EP0271438B1 (de) * | 1986-11-14 | 1992-04-29 | Ciba-Geigy Ag | Orales osmotisches System für Metoprolol mit verbesserten Formulierungseigenschaften |
-
1988
- 1988-04-25 US US07/185,564 patent/US4892739A/en not_active Expired - Lifetime
-
1989
- 1989-04-11 AU AU32687/89A patent/AU618083B2/en not_active Expired
- 1989-04-18 IL IL9001989A patent/IL90019A/en unknown
- 1989-04-20 PH PH38540A patent/PH27150A/en unknown
- 1989-04-21 CA CA000597406A patent/CA1334382C/en not_active Expired - Lifetime
- 1989-04-21 DD DD89327857A patent/DD288093A5/de not_active IP Right Cessation
- 1989-04-21 AT AT89107213T patent/ATE75939T1/de not_active IP Right Cessation
- 1989-04-21 EP EP89107213A patent/EP0339506B1/de not_active Expired - Lifetime
- 1989-04-21 ES ES198989107213T patent/ES2031302T3/es not_active Expired - Lifetime
- 1989-04-21 MX MX1575489A patent/MX15754A/es unknown
- 1989-04-21 NZ NZ228845A patent/NZ228845A/xx unknown
- 1989-04-21 DE DE8989107213T patent/DE58901373D1/de not_active Expired - Lifetime
- 1989-04-21 PT PT90341A patent/PT90341B/pt not_active IP Right Cessation
- 1989-04-21 FI FI891921A patent/FI90203C/fi not_active IP Right Cessation
- 1989-04-24 DK DK198901961A patent/DK175232B1/da not_active IP Right Cessation
- 1989-04-24 KR KR1019890005342A patent/KR0125935B1/ko active IP Right Grant
- 1989-04-24 NO NO891680A patent/NO175186C/no not_active IP Right Cessation
- 1989-04-24 ZA ZA892998A patent/ZA892998B/xx unknown
- 1989-04-24 IE IE131689A patent/IE61223B1/en not_active IP Right Cessation
- 1989-04-24 HU HU891961A patent/HU201469B/hu unknown
- 1989-04-24 JP JP1101829A patent/JP2750150B2/ja not_active Expired - Lifetime
-
1992
- 1992-08-11 GR GR920401014T patent/GR3005399T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH27150A (en) | Osmotic continuous dispensing oral delivery system containing a pharmaceutically acceptable active agent having improved core membrane adhesion properties | |
| CA1339079C (en) | Controlled release device with an impermeable coating having an orifice for release of drug | |
| US6881420B2 (en) | Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation | |
| EP0664118B1 (en) | Sustained-release tablet | |
| US6495162B2 (en) | Controlled release oral tablet having a unitary core | |
| US5229131A (en) | Pulsatile drug delivery system | |
| US6500459B1 (en) | Controlled onset and sustained release dosage forms and the preparation thereof | |
| AU666674B2 (en) | Dosage form for delivering drug in short-time period | |
| US4789549A (en) | Sustained release dosage forms | |
| CA2290531A1 (en) | Pharmaceutical formulation of omeprazole | |
| WO2002070021A1 (en) | Gastric delivery of antineoplastic agents and methods of treatment via inhibition of cancer cell using them | |
| CA2346988A1 (en) | Pharmaceutical formulation comprising omeprazole | |
| UA34458C2 (uk) | Дифузійно-осмотична фармацевтична система з регульованим виділенням ліків (варіанти) | |
| RU99126869A (ru) | Фармацевтический препарат омепразола | |
| CN102573811A (zh) | 缓释剂型 | |
| RU2214820C2 (ru) | Таблетированная фармацевтическая композиция | |
| EP0365947B1 (en) | Novel dosage form | |
| IE62597B1 (en) | Oral osmotic device for delivering nicotine | |
| US20050186273A1 (en) | Controlled release dosage form including a banded engine | |
| US20040058000A1 (en) | Controlled release capsule for delivery of liquid formulation | |
| US20030219485A1 (en) | Oral osmotic controlled drug delivery system | |
| JPH06256166A (ja) | 薬物放出制御製剤 | |
| FI102455B (fi) | Menetelmä oraalisen farmaseuttisen moniyksikköformulaation valmistamis eksi | |
| KR930003113B1 (ko) | 서방성 코팅 정제의 제조방법 |